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Introduction
Transcatheter aortic valve implantation (TAVI) is a less 
invasive than surgical aortic valve replacement (AVR) 
treatment modality for symptomatic severe aortic stenosis 
(AS). It is dedicated especially to elderly high-risk patients. 
Importantly, TAVI improves survival [1, 2] and quality of 
life (QoL) [3, 4] as compared to conservative treatment 
in inoperable patients. However, a successful TAVI pro-
cedure requires complex screening of patients, including 
detailed imaging as well as critical clinical assessment 
by an interdisciplinary Heart Team [5]. Longstanding AS 
results in pressure overload and subsequently concentric 
hypertrophy of the left ventricle with backward trans-
mission of increased left ventricular and left atrial filling 
pressures. These as well as secondary pulmonary vaso-
constriction and remodeling lead to secondary pulmo-
nary hypertension (PH) and tricuspid regurgitation (TR). 
Importantly, PH has been shown to be associated with 
worse early and late outcomes after AVR [6, 7]. Thus PH 
is an important determinant of surgical risk and a signifi-
cant component of the contemporary risk scores. However, 
the commonly used Society of Thoracic Surgeons score 
(STS) does not include PH as one of the risk factors dur-
ing mortality assessment [8], whereas the EuroSCORE 
only considers the presence of severe PH with systolic pul-
monary artery pressure (sPAP) >60  mm  Hg. In addition, 
PH has been associated with short- and mid-term mortal-
ity after TAVI, but evidence is inconsistent [9, 10]. TAVI 
has been shown to decrease sPAP significantly [11, 12], a 
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and had more frequently a history of previous stroke/tran-
sient ischemic attack (p = 0.019). A difference in all-cause 
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phenomenon associated with improved survival [13]. The 
recently updated European Society of Cardiology (ESC) 
and European Respiratory Society (ERS) guidelines on PH 
recommend using additional PH signs by assessing the ven-
tricles, pulmonary artery, and inferior vena cava and right 
atrium in addition to the continuous wave Doppler meas-
urement of the tricuspid regurgitant velocity (TRV) [14]. 
Thereby, PH probability is classified as “low”, “intermedi-
ate”, or “high”. We sought to investigate whether PH prob-
ability assessed by TRV only is a sufficient marker of clini-
cal outcomes and QoL after TAVI.
Materials and methods
A total of 148 consecutive patients who underwent TAVI at 
our center were included. All patients were diagnosed with 
symptomatic severe AS and had high surgical risk or con-
traindications for AVR. Patients were clinically evaluated to 
assess operative risk, comorbidities, frailty, and procedural 
feasibility. Baseline characteristics and procedural data 
were prospectively collected. Patient screening and selec-
tion were performed by a multidisciplinary Heart Team 
supported by clinical and imaging resources. As part of 
the pre-procedural work-up, all patients underwent a tran-
sthoracic echocardiogram before TAVI. According to the 
recently updated ESC/ERS guidelines for the diagnosis and 
management of PH [14], we assessed peak TRV for assign-
ing the echocardiographic PH probability. Patients were 
stratified as having “low” (TRV ≤2.8 m/s), “intermediate” 
(TRV 2.9–3.4 m/s), and “high” (TRV >3.4 m/s) probability 
of PH. Only the patients from the “high” probability group 
were considered as patients with PH—the PH (+) group. 
Remaining patients with “low” or “intermediate” prob-
ability of PH were considered as patients without PH—the 
PH (−) group. TAVI procedures were done using Edwards 
Sapien, Edwards Sapien XT, Edwards Sapien 3 (Edwards 
Lifesciences), Medtronic CoreValve (Medtronic, Inc), Jena-
Valve (JenaValve Technology), Lotus (Boston Scientific) 
and NVT (New Valve Technology). Access routes were 
transfemoral, transapical, subclavian, and direct aortic. Pro-
cedures were performed under general anesthesia or local 
anesthesia with sedation. All-cause mortality at 30 days, 12 
months and maximal available follow-up was assessed. In 
addition, occurrence of other events and QoL was collected 
as recommended by the Valve Academic Research Consor-
tium (VARC-2) [15]. QoL was assessed at baseline and at 
12 months after TAVI with the validated Polish version of 
the EQ-5D-3L questionnaire including the visual analog 
scale (VAS) score. The study was approved by the institu-
tional ethical board. Informed consent was obtained from 
all individual participants included in the study.
Statistical analysis
Results are presented as number of patients (percentages) 
or median [interquartile range (IQR)] where applicable. 
Differences between groups were tested using Chi square 
test and the Fisher’s exact test for dichotomous variables 
and the Mann–Whitney U test for continuous variables. 
Changes in the proportions of patients who reported either 
“no problems” or “some problems”/“extreme problems” on 
the EQ-5D-3L between baseline and follow-up visits were 
analyzed using McNemar’s test. Differences in the VAS 
score between baseline and follow-up assessments were 
analyzed with a Wilcoxon signed-rank test. All paired com-
parisons between baseline and 12-month measurements 
were performed excluding unpaired results. The difference 
in mortality between groups during follow-up was assessed 
by the Kaplan–Meier method. In addition, differences in 
outcomes are presented as adjusted for age and gender odds 
ratios (OR) with 95% confidence intervals (CI). In addi-
tion, multivariable Cox regression analysis was performed 
to find significant predictors of all-cause mortality at maxi-
mal follow-up. All baseline characteristics and procedural 
data were tested. Forward selection with a probability value 
for covariates to enter the model was set at the 0.05 level. 
Results are presented as hazard ratios (HR) with 95% CI. 
Receiver-operating characteristic (ROC) curve analysis 
was used to assess the ability of TRV to predict death at 
12 months and maximal available follow-up as well as the 
presence of reporting “some problems”/“extreme prob-
lems” on the EQ-5D-3L at baseline and 12 months. Results 
are presented as area under the ROC curve (AUC) with 
95% CI. All tests were two-tailed, and a p value <0.05 was 
considered statistically significant. All statistical analysis 
was performed using SPSS 15.0 (SPSS, Inc., Chicago, IL, 
USA).
Results
A total of 148 patients underwent elective TAVI. Median 
TRV was 3.3 (2.2–3.6) m/s. Of 148 patients, 65 (43.9%) 
patients had TRV >3.4  m/s and were considered as 
patients with PH. These patients presented with higher 
NYHA class at baseline (p = 0.027) and had more fre-
quently a history of previous stroke/transient ischemic 
attack (p = 0.019). Remaining patients, 41 (27.7%) patients 
with TRV ≤2.8  m/s and 42 (28.4%) patients with TRV 
2.9–3.4 m/s, were included in the PH (−) group. Detailed 
baseline clinical and procedural characteristics are shown 
in Tables  1 and 2. As shown in Table  3, in-hospital/30-
day and 12-month complications rates were comparable 
between patients with and without PH. A difference in 
mortality was noted at 12 months [PH (−) vs. PH (+): 9.6 
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vs. 21.5%; p = 0.043]; however, it was no longer signifi-
cant after adjustment for age and gender (OR 2.39, 95% 
CI 0.91–6.24; p = 0.08). On the contrary, unadjusted and 
adjusted rates of all-cause death at maximal follow-up of 
13.3 (6.0–31.1) months were higher in patients with PH 
(Table  3). ROC curve analysis confirmed the association 
between TRV and all-cause mortality at 12 months (AUC 
0.72, 95% CI 0.60–0.84; p = 0.001) and at maximal follow-
up (AUC 0.71, 95% CI 0.61–0.80; p < 0.001). Presence of 
TRV >3.4 m/s was able to predict death at 12 months with 
64% sensitivity and 62% specificity. The best performance 
was confirmed for cut-off value of 3.7 m/s which showed 
comparable sensitivity (60%) but much better specificity 
(82%). For maximal follow-up mortality, sensitivity was 
slightly lower with comparable results in terms of specific-
ity (TRV >3.4 m/s: sensitivity 58%, specificity 63%; TRV 
>3.7  m/s: sensitivity 52%, specificity 84%). Importantly, 
PH was not identified as an independent predictor of mor-
tality in multivariable Cox regression analysis. The only 
independent predictors were: incomplete coronary revas-
cularization [HR (95% CI): 5.45 (2.38–12.52); p = 0.001], 
estimated glomerular filtration rate [HR (95% CI) per 1 ml/
min/1.73  m2 increase: 0.96 (0.94–0.98); p = 0.001], and 
previous stroke/transient ischemic attack [HR (95% CI): 
Table 1  Baseline characteristics and echocardiographic data
AR = aortic regurgitation; AVA = aortic valve area; CABG = coronary artery bypass graft; COPD = chronic obstructive pulmonary disease; 
CTO = chronic total occlusion; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; IQR = interquartile range; LVEF = left 
ventricle ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; 
sPAP = systolic pulmonary artery pressure; STS = The Society of Thoracic Surgeons; TG = transaortic gradient; TIA = transient ischemic attack
All patients
N = 148
PH (−)
N = 83
PH (+)
N = 65
P value
Age, median (IQR) (years) 82.0 (77.0–85.0) 82.0 (77.0–85.0) 82.0 (78.0–84.0) 0.94
Age ≥80 years, n (%) 92 (62.2) 49 (59.0) 43 (66.2) 0.38
Men, n (%) 56 (37.8) 28 (33.7) 28 (43.1) 0.25
Body mass index, median (IQR) (kg/m2) 27.2 (25.2–30.6) 27.2 (25.4–29.3) 27.6 (25.3–31.5) 0.42
eGFR, median (IQR) (ml/min/1.73 m2) 56.5 (40.0–72.0) 54.5 (42.0–72.0) 59.5 (37.0–72.0) 0.86
NYHA class, n (%) 0.027
 I 0 (0.0) 0 (0.0) 0 (0.0)
 II 41 (27.7) 28 (33.7) 13 (20.0)
 III 97 (65.5) 47 (56.6) 50 (76.9)
 IV 10 (6.8) 8 (9.6) 2 (3.1)
Arterial hypertension, n (%) 139 (93.9) 77 (92.8) 62 (95.4) 0.73
Diabetes mellitus, n (%) 48 (32.4) 23 (27.7) 25 (38.5) 0.17
Atrial fibrillation, n (%) 52 (35.1) 29 (34.9) 23 (35.4) 0.96
Previous MI, n (%) 48 (32.4) 28 (33.7) 20 (30.8) 0.70
Previous PCI, n (%) 43 (29.1) 21 (25.3) 22 (33.8) 0.26
Previous CABG, n (%) 28 (18.9) 19 (22.9) 9 (13.8) 0.16
CTO, n (%) 14 (9.5) 5 (6.0) 9 (13.8) 0.11
Incomplete revascularization, n (%) 22 (14.9) 9 (10.8) 13 (20.) 0.12
COPD, n (%) 19 (12.8) 8 (9.6) 11 (16.9) 0.19
Stroke/TIA, n (%) 17 (11.5) 5 (6.0) 12 (18.5) 0.019
Pacemaker, n (%) 17 (11.5) 8 (9.6) 9 (13.8) 0.43
Logistic euroscore I, median (IQR) (%) 14.5 (10.0–22.7) 14.5 (10.0–22.0) 14.5 (10.5–23.5) 0.45
STS, median (IQR) (%) 6.2 (4.0–17.3) 6.0 (4.0–14.8) 7.3 (4.8–21.0) 0.22
TG max, median (IQR) (mmHg) 86.0 (69.0–103.0) 85.0 (66.5–97.0) 88.0 (72.5–111.0) 0.15
TG mean, median (IQR) (mmHg) 50.0 (42.0–63.0) 49.0 (41.0–58.0) 50.0 (44.5–65.5) 0.14
AVA, median (IQR)  [cm2] 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.6 (0.5–0.8) 0.06
LVEF, median (IQR) [%] 60.0 (50.0–65.0) 60.0 (48.0–65.0) 60.0 (50.0–65.0) 0.33
AR before, n (%) 0.70
 0 48 (32.4) 30 (36.1) 18 (27.7)
 1 75 (50.7) 40 (48.2) 35 (53.8)
 2 20 (13.5) 10 (12.0) 10 (15.4)
 3 5 (3.4) 3 (3.6) 2 (3.1)
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2.86 (1.17–7.00); p = 0.021]. Kaplan–Meier curves for sur-
vival after TAVI stratified by echocardiographic PH prob-
ability are shown in Fig.  1. Interestingly, we found that 
patients with “intermediate” probability of PH may have 
similar prognosis to those with “high” PH probability. All-
cause 12-month mortality in “low”, “intermediate” and 
“high” PH probability groups was: 4.9 vs. 14.3 vs. 21.5%; 
p = 0.06, respectively. Similarly, all-cause mortality at 
maximum follow-up was: 7.3 vs. 23.8 vs. 30.8%; p = 0.018, 
respectively. No differences between groups in all compo-
nents of EQ-5D-3L questionnaire were confirmed at 12 
months (Fig. 2). The median VAS at baseline [PH (−) vs. 
PH (+): 40.0 (30.0–57.5) vs. 40.0 (35.0–50.0); p = 0.80] 
and 12 months after TAVI [70.0 (60.0–77.5) vs. 70.0 
(62.5–80.0); p = 0.36] was comparable between groups. 
Similarly, no difference in VAS change during follow-up 
between both groups was reported [PH (−) vs. PH (+): 25.0 
(10.0–37.5) vs. 25.0 (15.0–40.0); p = 0.47]. In ROC curve 
analysis we failed to confirm any association between TRV 
and the presence of reporting “some problems”/“extreme 
problems” on the EQ-5D-3L questionnaire at baseline and 
12 months.
Discussion
The major finding of our study is that patients with severe 
AS and PH who undergone TAVI demonstrated higher 
long-term mortality than patients without PH but with 
comparable complications rate and QoL outcomes. Our 
Table 2  Procedural and echocardiographic data after the procedure
AR aortic regurgitation, LVEF left ventricle ejection fraction, TG transaortic gradient
All patients
N = 148
PH (−)
N = 83
PH (+)
N = 65
P value
General anesthesia 98 (69.5) 53 (67.1) 45 (72.6) 0.48
Access type, n (%) 0.83
 Transfemoral 117 (79.1) 66 (79.5) 51 (78.5)
 Transapical 28 (18.9) 16 (19.3) 12 (18.5)
 Transaortic 2 (1.4) 1 (1.2) 1 (1.5)
 Subclavian 1 (0.7) 0 (0.0) 1 (1.5)
Device implanted, n (%) 0.41
 Corevalve/Evolut R, n (%) 29 (19.6) 18 (21.7) 11 (16.9)
 Edwards Sapien 95 (64.2) 48 (57.8) 47 (72.3)
 Jena 10 (6.8) 7 (8.4) 3 (4.6)
 Lotus 9 (6.1) 7 (8.4) 2 (3.1)
 NVT 5 (3.4) 3 (3.6) 2 (3.1)
Prosthesis size, n (%) (mm) 0.82
 23 30 (20.3) 18 (21.7) 12 (18.5)
 25 8 (5.4) 5 (6.0) 3 (4.6)
 26 56 (37.8) 29 (34.9) 27 (41.5)
 27 8 (5.4) 5 (6.0) 3 (4.6)
 29 38 (25.7) 23 (27.7) 15 (23.1)
 31 8 (5.4) 3 (3.6) 5 (7.7)
Prosthesis size, median (IQR) (mm) 26.0 (25.0–29.0) 26.0 (25.0–29.0) 26.0 (26.0–29.0) 0.74
TG max after TAVI, median (IQR) (mmHg) 13.0 (10.0–19.0) 12.8 (10.0–19.0) 15.0 (10.1–19.0) 0.21
TG mean after TAVI, median (IQR) (mmHg) 7.4 (5.1–10.0) 7.0 (5.0–10.5) 8.0 (6.0–10.0) 0.29
LVEF after, median (IQR) (%) 48.0 (41.0–55.0) 47.0 (40.0–50.0) 50.0 (45.0–60.0) 0.15
AR after, n (%) 0.041
 0 84 (56.8) 45 (54.2) 39 (60.0)
 1 55 (37.2) 35 (42.2) 20 (30.8)
 2 7 (4.7) 1 (1.2) 6 (9.2)
 3 2 (1.4) 2 (2.4) 0 (0.0)
Radiation dose, median (IQR) (mGy) 721.0 (632.5–827.5) 721.0 (634.0–826.0) 721.0 (631.0–823.0) 0.83
Contrast medium load, median (IQR) (ml) 75.0 (50.0–137.5) 75.0 (50.0–100.0) 75.0 (75.0–150.0) 0.07
Fluoroscopy time, median (IQR) (min) 13.0 (12.0–15.0) 13.0 (11.5–15.0) 13.0 (12.0–14.0) 0.62
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findings are in line with results of the previous studies 
showing that PH is associated with an increased mortality 
after TAVI [6, 9–13, 16–18]. However, our study indicate 
that the outcomes of patients with “intermediate” probabil-
ity of PH might not be as good as expected and even simi-
lar to patients with “high” PH probability.
PH is observed quite frequent in patients with AS, as 
exercise induced PH is present in over half of the patients 
with severe asymptomatic AS [19]. Among patients under-
going TAVI, concomitant PH on echocardiography is 
found in 20–75% [6, 9–13, 16–18, 20]. However, different 
PH definitions and cut-off values may cause some incon-
sistence in assessing PH frequency. Importantly, exercise 
induced PH increased cardiac events in patients with severe 
asymptomatic AS [19]. Also, in patients undergoing surgi-
cal AVR for AS, baseline PH and its severity are associ-
ated with mortality, serious complications, and worse late 
survival [21–24]. Thus, patients with very elevated sPAP 
are often disqualified from surgical valve replacement due 
to concerns about high peri-operative morbidity and mor-
tality or doubts about whether or not valve replacement 
will provide any clinical benefit. Data on the impact of PH 
on outcomes after TAVI are less consistent. In the study 
by Lindman et  al. increased sPAP were associated with 
increased mortality, repeat hospitalizations, and strokes 
during the first year after TAVI [25]. Barbash et  al. [9] 
showed that the presence of sPAP >50 mmHg on echocar-
diography increased the mortality rate immediately after 
TAVI. In addition, patients with sPAP >50  mmHg had a 
prolonged hospitalization at the intensive care unit. Also, 
another studies have concluded a higher mortality rate at 
12 months among patients with PH [16–18]. On the con-
trary, in the FRANCE-2 registry [18], the 30-day outcome 
did not differ among 2435 TAVI patients with sPAP <40, 
40–60, and ≥60  mmHg as assessed by echocardiography. 
Similarly, Tamburino et  al. [26] did not identify sPAP 
>60  mmHg on echocardiography in TAVI patients as an 
independent predictor of 30-day mortality. However, in the 
recent meta-analysis by Tang et  al. on 9204 patients with 
severe AS undergoing TAVI, baseline PH was associated 
with increased 30-day and 1-year cardiovascular mortality 
as well as 1- and 2-year all-cause mortality [27].
Pulmonary artery pressures tend to decrease after AVR 
and after TAVI. However, some patients with severe pre-
operative PH have a persistent severe postprocedural eleva-
tion in sPAP, which is associated with a higher mortality 
Table 3  Clinical outcomes
AF atrial fibrillation, AKI acute kidney injury, TIA transient ischemic attack
a Derived from multivariable regression model—adjusted for age/gender
PH (−)
N = 83
PH (+)
N = 65
P value Adjusted OR (95% CI)* Adjusted P value
In-hospital/30-day
 Bleeding 25 (30.1) 24 (36.9) 0.38 1.36 (0.680–2.72) 0.39
 Blood transfusion 23 (27.7) 21 (32.3) 0.54 1.24 (0.61–2.54) 0.55
 AKI grade 3 2 (2.4) 6 (9.2) 0.14 3.93 (0.76–20.47) 0.10
 All-cause death 6 (7.2) 6 (9.2) 0.66 1.29 (0.39–4.22) 0.68
12-month
 Myocardial infarction 1 (1.2) 3 (4.6) 0.32 3.53 (0.35–35.92) 0.29
 Stroke/TIA 3 (3.6) 7 (10.8) 0.11 2.93 (0.71–12.03) 0.14
 New onset AF 3 (3.6) 7 (10.8) 0.11 2.77 (0.66–11.63) 0.16
 New permanent pacemaker 15 (18.1) 9 (13.8) 0.49 0.74 (0.30–1.83) 0.52
 All-cause death 8 (9.6) 14 (21.5) 0.043 2.39 (0.91–6.24) 0.08
Maximal follow-up
 All-cause death 13 (15.7) 20 (30.8) 0.028 2.26 (1.01–5.06) 0.047
Fig. 1  Kaplan–Meier curves for survival after transcatheter valve 
implantation stratified by echocardiographic pulmonary hypertension 
probability (low = thin line; intermediate = dotted line; high = thick 
line)
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than in patients with the decrease in sPAP [13]. TAVI was 
found to be beneficial in decreasing sPAP [10, 16, 17]. 
Importantly, Sinning et  al. found that in 16 patients with 
remaining high sPAP (>60 mmHg) at 3 months after TAVI, 
2-year mortality was higher as compared to 226 patients 
with sPAP reduced ≤60 mmHg [13]. It might suggest that 
both decrease in sPAP and PH severity during follow-up 
might impact the prognosis of patients after TAVI. Also, 
surgical data have demonstrated that the reoccurrence of 
preoperative PH is usually detected during longer follow-up 
of 3–4 years [28]. These may emphasize the value of longer 
follow-up in patients with baseline PH undergoing TAVI.
As mentioned, the frequency and assessed severity of 
PH may strongly depend on the definition used. Nijenhuis 
et al. found that [10] the new echocardiographic PH prob-
ability model incorporating additional PH signs performs 
well as a discriminator for prognosis after TAVI, irrespec-
tive of other patient and procedural characteristics. Patients 
with a “high” PH probability are at increased risk of early 
and late mortality compared to “low” and “intermediate” 
PH probability groups [10]. In our study, the probability of 
PH was estimated based on TRV only. However, it should 
be stressed that even this simplified approach of the assess-
ment of PH probability was sufficient to identify patients 
with elevated risk of death at follow-up. Also, TRV was 
able to discriminate patients with “intermediate” prob-
ability of PH whose may have similar prognosis to those 
with “high” PH probability. Probably, the assessment of 
additional PH signs might be particularly important for 
further evaluation and prediction of outcomes. In the study 
by Nijenhuis there were no differences in the occurrence 
or severity of a paravalvular leak, conduction disturbances, 
and the rate of thrombo-embolic or bleeding complications 
[10]. Compared to the “low” and “intermediate” PH prob-
ability, a “high” PH probability was more often associated 
with acute kidney injury, delirium, and prolonged hospitali-
zation [10]. On the contrary, no difference.
Evaluation of QoL seems to be an important index as 
frequently not a reduction in mortality but improvement in 
daily life comfort is most desirable by patients themselves 
[3, 4]. Importantly, patients with PH had a reduced QoL as 
compared to the general population [28]. Also, a decrease 
in QoL was shown to be a predictor of worse outcomes 
in adult patients with PH due to congenital heart disease 
[25911012]. On the contrary, the impact of PH on QoL in 
patients undergoing TAVI has not been tested so far. Ame-
lioration of QoL after TAVI was presented in recently pub-
lished studies [3, 4]. The improvement in QoL after TAVI 
Fig. 2  Proportions of patients that report either “some problems”/“extreme problems” for each category of the EQ-5D-3L at baseline and at 12 
months
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may be higher than observed after SAVR, even with the 
use of minimally-invasive surgical techniques (mini-thora-
cotomy, mini-sternotomy) [29]. In our study no differences 
in QoL were observed between groups. This might suggest 
equal response to TAVI in terms of QoL regardless of PH 
presence.
Study limitations
The presented study has several limitations. The most 
important is a single-center, prospective non-randomized 
observational design of the study. A relatively small cohort 
of included patients and the size of the two main groups 
have not allowed us for definitive confirmation/exclusion of 
the relationship between PH status and clinical outcomes 
of patients after TAVI. Right heart catheterization was not 
performed, limiting control for invasive measurements. 
Unfortunately, data on the PH assessment during follow-up 
were not available in all patients, thus limiting the possibil-
ity of correction for PH improvement. On the other hand, 
this study represents a comprehensive analysis of consecu-
tive patients without any exclusion criteria and complete 
assessment of QoL.
Conclusions
The presence of TRV >3.4  m/s indicating “high” prob-
ability of PH may predict impaired clinical outcomes after 
TAVI. No impact of PH on QoL outcomes was confirmed.
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